208 related articles for article (PubMed ID: 11396168)
21. Density functional theory and surface enhanced Raman spectroscopy characterization of novel platinum drugs.
Giese B; Deacon GB; Kuduk-Jaworska J; McNaughton D
Biopolymers; 2002; 67(4-5):294-7. PubMed ID: 12012451
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin.
Heudi O; Mercier-Jobard S; Cailleux A; Allain P
Biopharm Drug Dispos; 1999 Mar; 20(2):107-16. PubMed ID: 10206326
[TBL] [Abstract][Full Text] [Related]
25. Encapsulation of platinum anticancer drugs by apoferritin.
Yang Z; Wang X; Diao H; Zhang J; Li H; Sun H; Guo Z
Chem Commun (Camb); 2007 Sep; (33):3453-5. PubMed ID: 17700879
[TBL] [Abstract][Full Text] [Related]
26. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
27. Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method.
Rudnev AV; Aleksenko SS; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK
J Sep Sci; 2005 Feb; 28(2):121-7. PubMed ID: 15754818
[TBL] [Abstract][Full Text] [Related]
28. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
29. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
30. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of the interactions of cisplatin and carboplatin with nucleotides using UV resonance Raman spectroscopy.
Benson RL; Gustafson TL
Biopolymers; 1993 Nov; 33(11):1631-41. PubMed ID: 8241424
[TBL] [Abstract][Full Text] [Related]
32. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
33. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.
Fournier C; Hecquet B; Bastian G; Khayat D
Cancer Chemother Pharmacol; 1992; 29(6):461-6. PubMed ID: 1568289
[TBL] [Abstract][Full Text] [Related]
34. Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.
Hall MD; Telma KA; Chang KE; Lee TD; Madigan JP; Lloyd JR; Goldlust IS; Hoeschele JD; Gottesman MM
Cancer Res; 2014 Jul; 74(14):3913-22. PubMed ID: 24812268
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs.
Schmittgen TD; Ju JF; Danenberg KD; Danenberg PV
Int J Oncol; 2003 Sep; 23(3):785-9. PubMed ID: 12888918
[TBL] [Abstract][Full Text] [Related]
36. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
37. Uptake of platinum compounds in human tumors. In vitro study.
Hecquet B; Leroy A; Lefebvre JL; Peyrat JP; Adenis L
Bull Cancer; 1986; 73(5):535-41. PubMed ID: 3535936
[TBL] [Abstract][Full Text] [Related]
38. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
39. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro.
Sooriyaarachchi M; Narendran A; Gailer J
Metallomics; 2011 Jan; 3(1):49-55. PubMed ID: 21135941
[TBL] [Abstract][Full Text] [Related]
40. Three new asymmetric trans-amine(azole)dichloridoplatinum complexes that overcome cisplatin resistance and their reactions with 5'-GMP.
Pantoja E; Gallipoli A; van Zutphen S; Komeda S; Reddy D; Jaganyi D; Lutz M; Tooke DM; Spek AL; Navarro-Ranninger C; Reedijk J
J Inorg Biochem; 2006 Dec; 100(12):1955-64. PubMed ID: 17083978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
